Results 51 to 60 of about 1,753 (162)

Targeting Airway Remodeling in Severe Asthma: Is There a Window of Opportunity for Biologic Therapy Predicting Effects Using Causal Artificial Intelligence?

Allergy, EarlyView.
ABSTRACT Airway remodeling is increasingly recognized as a major determinant of asthma progression, fixed airflow limitation, and long‐term morbidity, particularly in severe disease. Although biologic therapies have transformed outcomes by reducing exacerbations and systemic corticosteroid exposure, their potential to modify structural airway ...
Sebastiano Gangemi, Sara Manti, Johann Christian Virchow, Giorgio Walter Canonica   +3 more
wiley   +1 more source

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

Allergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz, Salvador Iborra, Carlos Blanco, Ruperto González‐Pérez, Emilio Nuñez‐Borque, Can Zeyneloglu, Huseyn Babayev, Ozlem Göksel, Tuncay Göksel, Musa Khaitov, Dmitry Kudlay, Yadong Gao, Mustafa Sevim, Marie‐Charlotte Brüggen, Oral Alpan, Ming Wang, Luo Zhang, María J. Torres, Mohamed Shamji, Mübeccel Akdis, Kari C. Nadeau, Ismail Ogulur, Cezmi A. Akdis   +22 more
wiley   +1 more source

Anthropometric patterns in children with moderate‐to‐severe atopic dermatitis: Cross‐sectional insights from the TREATkids cohort

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives The relationship between atopic dermatitis (AD), weight, height, and body mass index (BMI) in children and adolescents and the impact of systemic treatments is controversial. We report the distribution of weight, height, and BMI in the German TREATkids cohort compared to a standardized German cohort (Kromeyer‐Hauschild)
Barbara Kind, Doreen Siegels, Hagen Ott, Susanne Abraham, René Sachse, Katharina Lönnecke, Inken Harder, Annice Heratizadeh, Katja Nemat, Christian Vogelberg, Dora Stölzl, Ines Gellhaus, Susanne Lau, Mehrak Yoosefi Moridani, Thomas Werfel, Stephan Weidinger, Jochen Schmitt, the TREATgermany study group   +17 more
wiley   +1 more source

The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis

Dermatology and Therapy
Introduction Lebrikizumab, a high-affinity IgG4 monoclonal antibody that selectively inhibits interleukin-13 with high binding affinity and slow dissociation rate, prevents the formation of the interleukin-4Rα/interleukin-13Rα1 heterodimer receptor ...
Jennifer Soung, Vivian Laquer, Joseph F. Merola, Angela Moore, Hany Elmaraghy, Chaoran Hu, Maria Lucia Buziqui Piruzeli, Evangeline Pierce, Esther Garcia Gil, Abel D. Jarell   +9 more
doaj   +1 more source

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This international, multicentre real‐world study of 148 patients’ documents treatment‐associated, bidirectional phenotype switching between psoriasis and atopic dermatitis. Psoriasis‐to‐eczematous switches occurred predominantly with IL‐17 and IL‐23 inhibitors, whereas AD‐to‐psoriasiform switches occurred exclusively during treatment with biologic ...
Tiago Torres, Mario Valenti, Anna Balato, Matteo Megna, Paolo Gisondi, Vimal Prajapati, Stefano Piaserico, Julia‐Tatjana Maul, Lara Valeska Maul, Jose Manuel Carrascosa, Francisco José Navarro‐Triviño, Elizabeth Lazaridou, César Ferreira, Jacopo Tartaglia, Christian Ciolfi, Athina‐Ioanna Daponte, Eugenia Veronica Di Brizzi, Maddalena Napolitano, Barbara Leal Guerra, Monica Munera‐Campos, Siddhartha Sood, Silvia Ferruci, Francesca Prignano, Esteban Dauden, Mar Llamas‐Velasco, Ron Vender, Jensen Yeung, Angelo Marzano, Luis Puig   +28 more
wiley   +1 more source

Lebrikizumab: a new anti-IL-13 agent for treating moderate-to-severe atopic dermatitis [PDF]

Introduction: Atopic dermatitis (AD) is a common chronic inflammatory skin disease. Moderate-to-severe AD severely affects patients’ quality of life. New drugs selectively targeting molecular pathways involved in the pathogenesis of the disease led to ...
Luca Stingeni, Cataldo Patruno, Amerio, Paolo, Caterina Foti, Paolo Amerio, Girolomoni, Giampiero, Silvia Ferrucci, Stingeni, Luca, Foti, Caterina, Giampiero Girolomoni, Ferrucci, Silvia, Patruno, Cataldo   +11 more
core   +1 more source

Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In adults with moderate AD post‐TCS and ‐TCI, who may otherwise be eligible for systemic therapy, 1.5% ruxolitinib cream improved clinical signs and symptoms in the TRuE‐AD4 study. Abstract Background In patients with moderate atopic dermatitis (AD), topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) often do not sufficiently ...
José Manuel Carrascosa, Vimal H. Prajapati, H. Chih‐ho Hong, Viktoria Eleftheriadou, Athanasios Tsianakas, Alexander A. Navarini, Ketty Peris, Eingun James Song, Raj Chovatiya, Sébastien Barbarot, Konstantin Popovic, Haq Nawaz, Qian Li, Vivek Purohit, Andreas Wollenberg   +14 more
wiley   +1 more source

HPV‐6 Positive Eruptive Verruca Vulgaris After Upadacitinib Initiation for Severe Atopic Dermatitis

JEADV Clinical Practice, Volume 5, Issue 3, Page 974-978, September 2026.
ABSTRACT Oral JAK‐1 inhibitors for atopic dermatitis (AD) are associated with an increased risk of cutaneous viral infections, particularly herpes zoster. Emerging case reports further suggest a link to eruptive human papillomavirus (HPV) disease. A 23‐year‐old transgender man (female‐to‐male) with severe AD developed a rapidly disseminating eruption ...
Mohammed Shanshal, Emily Moon, Georgios Kallikas   +2 more
wiley   +1 more source

Lebrikizumab. Anti-interleukin-13 monoclonal antibody Treatment of asthma

, 2014
Current advances in the knowledge of asthma pathobiology suggest that anti-cytokine therapies may be potentially useful for the treatment of this complex and heterogeneous airway disease. In particular, given the key role played by interleukin-13 (IL-13)
Rosario Maselli, Luca Gallelli, VATRELLA, Alessandro, Maria Teresa Busceti, Rosa Terracciano, Girolamo Pelaia   +5 more
core   +1 more source

Evidence Summary of Pruritus Management in Patients With Atopic Dermatitis: Implications for Nursing Practice

Journal of Cosmetic Dermatology, Volume 25, Issue 9, September 2026.
ABSTRACT Background To synthesize the most current and relevant evidence regarding pruritus management in patients with atopic dermatitis (AD), and to identify implications for nursing assessment, education, monitoring, and follow‐up. Method An extensive literature search was conducted across multiple databases, including the Cochrane Library, Embase ...
Yuzhen Shen, Qian Shen, Manni Chen, Rufang Liu   +3 more
wiley   +1 more source